Boothbay Fund Management’s NextCure NXTC Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
– Sell
-84,687
Closed -$135K – 2383
2026
Q2
$135K Buy
84,687
+15,070
+22% +$111K ﹤0.01% 2004
2026
Q1
$744K Hold
69,617
– – 0.01% 1118
2025
Q4
$988K Buy
+69,617
New +$721K 0.01% 808
2022
Q2
– Sell
-1,123
Closed -$65K – 2547
2022
Q1
$65K Hold
1,123
– – ﹤0.01% 2152
2021
Q4
$81K Sell
1,123
-3,140
-74% -$263K ﹤0.01% 1736
2021
Q3
$345K Sell
4,263
-1,050
-20% -$92.1K 0.01% 1261
2021
Q2
$512K Buy
5,313
+1,006
+23% +$103K 0.02% 990
2021
Q1
$517K Buy
4,307
+2,391
+125% +$346K 0.02% 931
2020
Q4
$251K Hold
1,916
– – 0.01% 1017
2020
Q3
$202K Buy
+1,916
New +$236K 0.01% 944

Other funds holding NXTC

Boothbay Fund Management's NXTC Position: Q3 2026 in Review

Boothbay Fund Management sold out of NextCure (NXTC) in Q3 2026, closing a stake of 84,687 shares — an estimated $135K sold.

Boothbay Fund Management first reported a position in NXTC in Q3 2020 and held it in 10 quarters. The position peaked at $988K in Q4 2025. 29 funds tracked by Wall St. Rank hold NXTC as of Q3 2026.

  • Boothbay Fund Management reported no remaining NextCure position as of Q3 2026 after selling out during the quarter.
  • Boothbay Fund Management sold 84,687 NextCure shares in Q3 2026, an estimated $135K.
  • Boothbay Fund Management first reported a position in NextCure in Q3 2020 and held it in 10 quarters.
  • Boothbay Fund Management's NextCure position peaked at $988K in Q4 2025.
  • 29 funds tracked by Wall St. Rank held NextCure as of Q3 2026.

Based on Boothbay Fund Management's 13F filing for Q3 2026, filed 16 Nov 2026.